Pharma Co. Brass Face Investor Suit Over Drug Trial Probe

By Emilie Ruscoe · December 13, 2024, 7:53 PM EST

Officers and directors of cancer treatment developer MacroGenics Inc. have been hit with a shareholder derivative action alleging they breached their fiduciary duties after the company announced three study participant deaths...

To view the full article, register now.
Try a seven day FREE Trial

Already a subscriber? Click here to login

Documents

Related Sections

Case Information

Case Title

Cottle v. Macrogenics, Inc. et al

Case Number

8:24-cv-03578

Court

Maryland

Nature of Suit

Securities/Commodities

Date Filed

December 11, 2024